About the Company
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California, and it serves more than 155 countries. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Illumina's customers include genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies.
Sector
Industrial Applications and Services
Industry
Laboratory Analytical Instruments
Employees
10007
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ILMN News
Illumina (NASDAQ:ILMN) investors are sitting on a loss of 71% if they invested three years ago
It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we ...
EU approves Illumina's plan to divest cancer test maker Grail
The EU's executive Commission approved Illumina's plan to unwind its completed acquisition of cancer diagnostic test maker ...
Illumina’s Grail divestment approved by EU (update)
The EU regulators on Friday approved plans by U.S. genomics company Illumina (NASDAQ:ILMN) to divest Grail, the cancer test ...
What the Options Market Tells Us About Illumina
The general mood among these heavyweight investors is divided, with 47% leaning bullish and 52% bearish. Among these notable ...
Illumina's planned divestment of GRAIL approved by the European Commission
SAN DIEGO, April 12, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has received approval of its divestment plan ...
Icahn Loses Appeal of Order in Ongoing Delaware Illumina Suit
Delaware’s highest court refused to hear billionaire investor Carl Icahn’s appeal of an order to remove confidential ...
Illumina gets two new executives as the San Diego biotech revamps its C-suite
Ankur Dhingra will take over as Illumina’s new chief financial officer starting April 15, the company announced Tuesday.
Illumina CFO departs, replacement named along with chief strategy officer
Illumina (Nasdaq:ILMN) announced that it appointed Ankur Dhingra as CFO following the departure of Joydeep Goswami.
Illumina (ILMN) Maintains Strong Guidance and Strategic Leadership Appointments
Leerink Partners analyst Puneet Souda has reiterated their bullish stance on ILMN stock, giving a Buy rating on April 10. Puneet Souda’s ...
Pillar Biosciences oncoReveal™ CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the Illumina MiSeq™ Dx System
Company continues to execute on its global strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable ...
Illumina: Engineering a Cool Career in Biotech - and Volunteering Along the Way
What kind of opportunities can an engineer find through their work? Plenty, at Illumina! One employee shares how she makes a difference.Originally published on Illumina News Center NORTHAMPTON, MA / A ...
Illumina: Evidence Supports Sequencing As First-Line Rare Disease Diagnostic
The Medical Genome Initiative presents a paper in an effort to expand patient access to sequencingOriginally published on Illumina News CenterNORTHAMPTON, MA / ACCESSWIRE / April 17, 2024 / A recent l ...
Loading the latest forecasts...